Q1 2025 Holdings
Filed 2025-05-15 | 33 holdings | $6.4B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| United Therapeutics Corp(UTHR) | Common | 91307C102 | $824.6M | 2,675,000 | 12.9% |
| Ascendis Pharma(ASND) | Sponsored ADR | 04351P101 | $813.3M | 5,218,000 | 12.7% |
| Argenx SE(ARGX) | Sponsored ADR | 04016X101 | $731.1M | 1,235,177 | 11.4% |
| Madrigal Pharmaceuticals Inc(MDGL) | Common | 558868105 | $669.8M | 2,022,222 | 10.5% |
| Krystal Biotech Inc(KRYS) | Common | 501147102 | $492.4M | 2,731,000 | 7.7% |
| Blueprint Medicines Corp(2L9) | Common | 09627Y109 | $340.8M | 3,850,000 | 5.3% |
| Apellis Pharmaceuticals Inc.(APLS) | Common | 03753U106 | $267.3M | 12,222,222 | 4.2% |
| Avidity Biosciences Inc(RNA) | Common | 05370A108 | $225.1M | 7,625,000 | 3.5% |
| Xenon Pharmaceuticals Inc(XENE) | Common | 98420N105 | $192.6M | 5,741,666 | 3.0% |
| Soleno Therapeutics Inc(SLNO) | Common | 834203309 | $180.4M | 2,525,000 | 2.8% |
| Kymera Therapeutics Inc(KYMR) | Common | 501575104 | $176.8M | 6,460,000 | 2.8% |
| Sarepta Therapeutics Inc(SRPT) | Common | 803607100 | $170.7M | 2,674,835 | 2.7% |
| Amicus Therapeutics Inc.(FOLD) | Common | 03152W109 | $167.3M | 20,500,000 | 2.6% |
| Arrowhead Pharmaceuticals Inc.(ARWR) | Common | 04280A100 | $141.6M | 11,111,111 | 2.2% |
| Vera Therapeutics Inc(VERA) | Common | 92337R101 | $137.0M | 5,701,900 | 2.1% |
| Merus N V | Common | N5749R100 | $126.3M | 3,000,000 | 2.0% |
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $108.2M | 2,770,100 | 1.7% |
| Intra-Cellular Therapies Inc(ITCIEUR) | Common | 46116X101 | $82.5M | 625,000 | 1.3% |
| Alkermes PLC(ALKS) | Common | G01767105 | $80.9M | 2,450,000 | 1.3% |
| Biocryst Pharmaceuticals Inc(BCRX) | Common | 09058V103 | $65.3M | 8,700,000 | 1.0% |
| Ocular Therapeutix Inc(OCUL) | Common | 67576A100 | $59.1M | 8,060,000 | 0.9% |
| Centessa Pharmaceuticals PLC(CNTA) | SPONSORED ADR | 152309100 | $58.2M | 4,050,000 | 0.9% |
| 89Bio Inc(ETNBGBP) | Common | 282559103 | $46.2M | 6,350,000 | 0.7% |
| Mannkind Corp(MNKD) | Common | 56400P706 | $44.0M | 8,750,000 | 0.7% |
| Vaxcyte Inc(PCVX) | Common | 92243G108 | $37.8M | 1,000,000 | 0.6% |
| Tourmaline BIO Inc(TRML) | Common | 89157D105 | $36.9M | 2,425,000 | 0.6% |
| Ultragenyx Pharmaceutical Inc(RARE) | Common | 90400D108 | $30.1M | 830,000 | 0.5% |
| Taysha Gene Therapies Inc(TSHA) | Common | 877619106 | $27.8M | 19,999,999 | 0.4% |
| Uniqure NV(QURE) | Common | N90064101 | $23.1M | 2,175,000 | 0.4% |
| Monte Rosa Therapeutics Inc(GLUE) | Common | 61225M102 | $21.6M | 4,645,548 | 0.3% |
| Autolus Therapeutics PLC(AUTL) | Sponsored ADR | 05280R100 | $15.4M | 9,910,642 | 0.2% |
| Septerna Inc(SEPN) | Common | 81734D104 | $7.7M | 1,337,500 | 0.1% |
| Whitehawk Therapeutics Inc(WHWK) | Common | 00032Q104 | $5.1M | 2,849,402 | 0.1% |